Contraceptive counseling and use among women with systemic lupus erythematosus: A gap in health care quality?

Arthritis Care and Research

Volumn 63, Issue 3, 2011, Pages 358-365

  Yazdany, Jinoos ^a   Trupin, Laura ^a   Kaiser, Rachel ^a   Schmajuk, Gabriela ^b   Gillis, Joann Zell ^c   Chakravarty, Eliza ^b   Schwarz, Eleanor Bimla ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

^c DEPARTMENT OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; TERATOGENIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CHI SQUARE TEST; CONTROLLED STUDY; FEMALE; HEALTH CARE QUALITY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PATIENT COUNSELING; PREGNANCY; PREMENOPAUSE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; UNPLANNED PREGNANCY; CHI SQUARE DISTRIBUTION; CONGENITAL MALFORMATION; CONTRACEPTION; COUNSELING; CROSS-SECTIONAL STUDY; METHODOLOGY; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; UNITED STATES;

ABNORMALITIES, DRUG-INDUCED; ADULT; CHI-SQUARE DISTRIBUTION; CONTRACEPTION; COUNSELING; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; ODDS RATIO; PREGNANCY; PREGNANCY, UNPLANNED; RISK ASSESSMENT; RISK FACTORS; SAN FRANCISCO; YOUNG ADULT;

EID: 79958103071     PISSN: 00043591     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.20402     Document Type: Article

References (46)

1. Rahman FZ, Rahman J, Al-Suleiman SA, Rahman MS. Pregnancy outcome in lupus nephropathy. Arch Gynecol Obstet 2005;271:222-6. (Pubitemid 40562099)
2. Wagner SJ, Craici I, Reed D, Norby S, Bailey K, Wiste HJ, et al. Maternal and foetal outcomes in pregnant patients with active lupus nephritis. Lupus 2009;18:342-7.
3. Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005;52:514-21. (Pubitemid 40216315)
4. Jungers P, Dougados M, Pelissier C, Kuttenn F, Tron F, Le-savre P, et al. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 1982;25:618-23. (Pubitemid 12078974)
5. Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;142:953-62.
6. Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, Mestanza-Peralta M, Lara-Reyes P, Seuc AH, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005;353:2539-49. (Pubitemid 41785891)
7. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sam-maritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353: 2550-8. (Pubitemid 41785892)
8. Culwell KR, Curtis KM, del Carmen Cravioto M. Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. Obstet Gynecol 2009;114: 341-53.
9. Yelin E, Trupin L, Katz P, Criswell L, Yazdany J, Gillis J, et al. Work dynamics among persons with systemic lupus erythem-atosus. Arthritis Rheum 2007;57:56-63.
10. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25: 1271-7. (Pubitemid 13221242)
11. Schwarz EB, Lohr PA, Gold MA, Gerbert B. Prevalence and correlates of ambivalence towards pregnancy among nonpreg-nant women. Contraception 2007;75:305-10. (Pubitemid 46385924)
12. Kavanaugh ML, Schwarz EB. Prospective assessment of pregnancy intentions using a single-versus a multi-item measure. Perspect Sex Reprod Health 2009;41:238-43.
13. Karlson EW, Daltroy LH, Rivest C, Ramsey-Goldman R, Wright EA, Partridge AJ, et al. Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies. Lupus 2003;12:280-6. (Pubitemid 36458658)
14. Yazdany J, Yelin EH, Panopalis P, Trupin L, Julian L, Katz PP. Validation of the Systemic Lupus Erythematosus Activity Questionnaire in a large observational cohort. Arthritis Rheum 2008;59:136-43. (Pubitemid 351171889)
15. Buchanan NM, Toubi E, Khamashta MA, Lima F, Kerslake S, Hughes GR. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 1996;55:486-8. (Pubitemid 26249027)
16. Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006;54:3640-7. (Pubitemid 44737176)
17. Khamashta MA, Buchanan NM, Hughes GR. The use of hy-droxychloroquine in lupus pregnancy: the British experience. Lupus 1996;5 Suppl 1:S65-6. (Pubitemid 26196745)
18. Levy RA, Vilela VS, Cataldo MJ, Ramos RC, Duarte JL, Tura BR, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001;10: 401-4. (Pubitemid 32578614)
19. Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Stewart FH, Kowal D. Contraceptive technology: nineteenth revised edition. New York: Ardent Media; 2007.
20. Schwarz EB, Manzi S. Risk of unintended pregnancy among women with systemic lupus erythematosus. Arthritis Rheum 2008;59:863-6. (Pubitemid 351847570)
21. Ekblom-Kullberg S, Kautiainen H, Alha P, Helve T, Leirisalo-Repo M, Julkunen H. Reproductive health in women with systemic lupus erythematosus compared to population controls. Scand J Rheumatol 2009;38:375-80.
22. Brown SS, Eisenberg L, editors. The best intentions: unintended pregnancy and the well-being of children and families. Washington (DC): National Academy Press; 1995.
23. Clowse ME, Magder LS, Witter F, Petri M. Early risk factors for pregnancy loss in lupus. Obstet Gynecol 2006;107:293-9.
24. Hayslett JP. Maternal and fetal complications in pregnant women with systemic lupus erythematosus. Am J Kidney Dis 1991;17:123-6.
25. Bobrie G, Liote F, Houillier P, Grunfeld JP, Jungers P. Pregnancy in lupus nephritis and related disorders. Am J Kidney Dis 1987;9:339-43. (Pubitemid 17089644)
26. US Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins; 1996.
27. Moos MK, Bartholomew NE, Lohr KN. Counseling in the clinical setting to prevent unintended pregnancy: an evidence-based research agenda. Contraception 2003;67:115-32. (Pubitemid 36174011)
28. Lopez LM, Steiner MJ, Grimes DA, Schulz KF. Strategies for communicating contraceptive effectiveness. Cochrane Database Syst Rev 2008;2:CD006964.
29. Weisman CS, Maccannon DS, Henderson JT, Shortridge E, Orso CL. Contraceptive counseling in managed care: preventing unintended pregnancy in adults. Womens Health Issues 2002;12:79-95. (Pubitemid 34168526)
30. Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, MacLean CH, Wofsy D, et al. A quality indicator set for systemic lupus erythematosus. Arthritis Rheum 2009;61:370-7.
31. Farr S, Folger SG, Paulen M, Tepper N, Whiteman M, Zapata L, et al. U.S. medical eligibility criteria for contraceptive use, 2010: adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition. MMWR Recomm Rep 2010;59:1-86.
32. World Health Organization. Medical eligibility criteria for contraceptive use: 4th ed. 2009. URL: http://www.who.int/reproductivehealth/publications/ family-planning/978924156 3888/en/index.html.
33. Kohn L, Corrigan J, Donaldson M, editors. To err is human: building a safer health system. Washington (DC): National Academy Press; 1999.
34. ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006;107:1453-72.
35. Culwell KR, Curtis KM. Use of contraceptive methods by women with current venous thrombosis on anticoagulant therapy: a systematic review. Contraception 2009;80:337-45.
36. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives: results of an international, multicenter, case-control study. Contraception 1998;57:315-24.
37. Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idio-pathic venous thromboembolism in users of progestogens alone letter. Lancet 1999;354:1610-1. (Pubitemid 29515957)
38. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890.
39. Schwarz EB, Longo LS, Zhao X, Stone RA, Cunningham F, Good CB. Provision of potentially teratogenic medications to female veterans of childbearing age. Med Care 2010;48:834-42.
40. Schwarz EB, Maselli J, Norton M, Gonzales R. Prescription of teratogenic medications in United States ambulatory practices. Am J Med 2005;118:1240-9. (Pubitemid 41566525)
41. Schwarz EB, Postlethwaite DA, Hung YY, Armstrong MA. Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women. Ann Intern Med 2007;147:370-6. (Pubitemid 351664537)
42. Jones RK, Kost K. Underreporting of induced and spontaneous abortion in the United States: an analysis of the 2002 National Survey of Family Growth. Stud Fam Plann 2007;38: 187-97. (Pubitemid 47382382)
43. Stuart GS, Grimes DA. Social desirability bias in family planning studies: a neglected problem. Contraception 2009;80: 108-12.
44. Piccinino LJ, Mosher WD. Trends in contraceptive use in the United States: 1982-1995. Fam Plann Perspect 1998;30: 4-10, 46.
45. Postlethwaite D, Trussell J, Zoolakis A, Shabear R, Petitti D. A comparison of contraceptive procurement pre-and post-benefit change. Contraception 2007;76:360-5. (Pubitemid 47610761)
46. Sonfield A, Gold RB, Frost JJ, Darroch JE. U.S. insurance coverage of contraceptives and the impact of contraceptive coverage mandates, 2002. Perspect Sex Reprod Health 2004; 36:72-9. (Pubitemid 38578403)